




Naftifine

Revised: October 31, 2018.

CASRN: 65472-88-0



Drug Levels and Effects

Summary of Use during Lactation

Topical naftifine has not been studied during breastfeeding. Because only 4 to 6% is absorbed after topical application, it is considered a low risk to the nursing infant.[1] Avoid application to the nipple area and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Only water-miscible cream, gel or liquid products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.[2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Terbinafine

References

1. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. *Dermatol Clin.* 2006;24:167-97. PubMed PMID: 16677965.
2. Noti A, Grob K, Biedermann M et al. Exposure of babies to C(15)-C(45) mineral paraffins from human milk and breast salves. *Regul Toxicol Pharmacol.* 2003;38:317-25. PubMed PMID: 14623482.

Substance Identification

Substance Name

Naftifine

CAS Registry Number

65472-88-0

Drug Class

Breast Feeding

Lactation

Anti-Infective Agents

Antifungal Agents